SCYNEXIS, Inc. (SCYX)
NCM · Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
April 2026
SCYNEXIS seeks shareholder approval for board nominees and share increases
# 📜 What This Document Is 🗳️ This document is a Preliminary Proxy Statement, which is essentially a mandatory educational guide for shareholders. It was filed by SCYNEXIS, Inc., to prepare investors for their 2026 Annual Meeting of Stockholders. 👉 The primary purpose is to tell you exactly what
March 2026
SCYNEXIS INC — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, a report companies use to announce major events to investors. In this case, SCYNEXIS is announcing it has **completed the acquisition** of a new drug candidate called PXL-770 (now named SCY-770) from a French company, Poxel S.A. It’s a press rele
SCYNEXIS INC — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing from SCYNEXIS, a biotech company. Attached is the main event: a **Securities Purchase Agreement**. Think of it as a formal IOU and rulebook for a major cash deal. The company is selling stock and warrants to a group of investors to raise money. This d
SEC filings
All filings →Insider trades
All insider trades →SCYNEXIS, Inc. has no reported insider trades in the last 90 days.